232 related articles for article (PubMed ID: 31825160)
21. NGS testing for cardiomyopathy: Utility of adding RASopathy-associated genes.
Ceyhan-Birsoy O; Miatkowski MM; Hynes E; Funke BH; Mason-Suares H
Hum Mutat; 2018 Jul; 39(7):954-958. PubMed ID: 29696744
[TBL] [Abstract][Full Text] [Related]
22. [Update on the treatment of RASopathies].
Duat-Rodriguez A; Hernandez-Martin A
Rev Neurol; 2017 May; 64(s03):S13-S17. PubMed ID: 28524213
[TBL] [Abstract][Full Text] [Related]
23. RASopathies: Dermatologists' viewpoints.
Palit A; Inamadar AC
Indian J Dermatol Venereol Leprol; 2022; 88(4):452-463. PubMed ID: 35138057
[TBL] [Abstract][Full Text] [Related]
24. Copy number variants including RAS pathway genes-How much RASopathy is in the phenotype?
Lissewski C; Kant SG; Stark Z; Schanze I; Zenker M
Am J Med Genet A; 2015 Nov; 167A(11):2685-90. PubMed ID: 25974318
[TBL] [Abstract][Full Text] [Related]
25. [New insight of craniofacial and oral findings of the RASopathies].
Cao HT; Yang YJ; Zheng Q; Shi B; Li CH
Zhonghua Kou Qiang Yi Xue Za Zhi; 2018 Dec; 53(12):858-861. PubMed ID: 30522213
[TBL] [Abstract][Full Text] [Related]
26. RASopathies: The musculoskeletal consequences and their etiology and pathogenesis.
Fowlkes JL; Thrailkill KM; Bunn RC
Bone; 2021 Nov; 152():116060. PubMed ID: 34144233
[TBL] [Abstract][Full Text] [Related]
27. The third international meeting on genetic disorders in the RAS/MAPK pathway: towards a therapeutic approach.
Korf B; Ahmadian R; Allanson J; Aoki Y; Bakker A; Wright EB; Denger B; Elgersma Y; Gelb BD; Gripp KW; Kerr B; Kontaridis M; Lazaro C; Linardic C; Lozano R; MacRae CA; Messiaen L; Mulero-Navarro S; Neel B; Plotkin S; Rauen KA; Roberts A; Silva AJ; Sittampalam SG; Zhang C; Schoyer L
Am J Med Genet A; 2015 Aug; 167A(8):1741-6. PubMed ID: 25900621
[TBL] [Abstract][Full Text] [Related]
28. Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes.
Kratz CP; Franke L; Peters H; Kohlschmidt N; Kazmierczak B; Finckh U; Bier A; Eichhorn B; Blank C; Kraus C; Kohlhase J; Pauli S; Wildhardt G; Kutsche K; Auber B; Christmann A; Bachmann N; Mitter D; Cremer FW; Mayer K; Daumer-Haas C; Nevinny-Stickel-Hinzpeter C; Oeffner F; Schlüter G; Gencik M; Überlacker B; Lissewski C; Schanze I; Greene MH; Spix C; Zenker M
Br J Cancer; 2015 Apr; 112(8):1392-7. PubMed ID: 25742478
[TBL] [Abstract][Full Text] [Related]
29. RAS diseases in children.
Niemeyer CM
Haematologica; 2014 Nov; 99(11):1653-62. PubMed ID: 25420281
[TBL] [Abstract][Full Text] [Related]
30. An attenuated phenotype of Costello syndrome in three unrelated individuals with a HRAS c.179G>A (p.Gly60Asp) mutation correlates with uncommon functional consequences.
Gripp KW; Sol-Church K; Smpokou P; Graham GE; Stevenson DA; Hanson H; Viskochil DH; Baker LC; Russo B; Gardner N; Stabley DL; Kolbe V; Rosenberger G
Am J Med Genet A; 2015 Sep; 167A(9):2085-97. PubMed ID: 25914166
[TBL] [Abstract][Full Text] [Related]
31. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway.
Tidyman WE; Rauen KA
Expert Rev Mol Med; 2008 Dec; 10():e37. PubMed ID: 19063751
[TBL] [Abstract][Full Text] [Related]
32. Molecular Genetics of Noonan Syndrome and RASopathies.
Liao J; Mehta L
Pediatr Endocrinol Rev; 2019 May; 16(Suppl 2):435-446. PubMed ID: 31115195
[TBL] [Abstract][Full Text] [Related]
33. Clinical manifestations of mutations in RAS and related intracellular signal transduction factors.
Zenker M
Curr Opin Pediatr; 2011 Aug; 23(4):443-51. PubMed ID: 21750428
[TBL] [Abstract][Full Text] [Related]
34. The impact of RASopathy-associated mutations on CNS development in mice and humans.
Kang M; Lee YS
Mol Brain; 2019 Nov; 12(1):96. PubMed ID: 31752929
[TBL] [Abstract][Full Text] [Related]
35. New prospectives on treatment opportunities in RASopathies.
Gelb BD; Yohe ME; Wolf C; Andelfinger G
Am J Med Genet C Semin Med Genet; 2022 Dec; 190(4):541-560. PubMed ID: 36533679
[TBL] [Abstract][Full Text] [Related]
36. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
Aoki Y; Niihori T; Narumi Y; Kure S; Matsubara Y
Hum Mutat; 2008 Aug; 29(8):992-1006. PubMed ID: 18470943
[TBL] [Abstract][Full Text] [Related]
37. Deregulated Ras signaling in developmental disorders: new tricks for an old dog.
Schubbert S; Bollag G; Shannon K
Curr Opin Genet Dev; 2007 Feb; 17(1):15-22. PubMed ID: 17208427
[TBL] [Abstract][Full Text] [Related]
38. Rasopathies case report: concurrence of two pathogenic variations de novo in NF1 and KRAS genes in a patient.
Baquedano Lobera I; Izquierdo Álvarez S; Oliván Del Cacho MJ
BMC Pediatr; 2019 Apr; 19(1):92. PubMed ID: 30953504
[TBL] [Abstract][Full Text] [Related]
39. Copy number variants and rasopathies: germline KRAS duplication in a patient with syndrome including pigmentation abnormalities.
Gilbert-Dussardier B; Briand-Suleau A; Laurendeau I; Bilan F; Cavé H; Verloes A; Vidaud M; Vidaud D; Pasmant E
Orphanet J Rare Dis; 2016 Jul; 11(1):101. PubMed ID: 27450488
[TBL] [Abstract][Full Text] [Related]
40. Cell type-specific roles of RAS-MAPK signaling in learning and memory: Implications in neurodevelopmental disorders.
Ryu HH; Lee YS
Neurobiol Learn Mem; 2016 Nov; 135():13-21. PubMed ID: 27296701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
